 A peer-reviewed scientific article has underscored the potential of Tiziana Life Sciences PLC LSE:TILS, NASDAQ:TLSA, FRA:RTRA, OTC:TIZAFs monoclonal antibody nasal spray in people with mild-to-moderate Covid. The report in the Frontiers in Immunology showed Foralumab produced a significant reduction in lung inflammation as assessed by a CT scan. 